ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered
ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…
CertaraJuly 23, 2025
The end of animal testing? Transitioning to models is promising — but no silver bullet
The FDA has stated that the pharma industry must transition to using in vitro assays,…
CertaraJuly 21, 2025
MIDD can ease pediatric & rare disease drug loss in Japan
Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…
CertaraJuly 8, 2025
Accelerating Oncology Drug FDA RTOR Submission with Project Management Services
Discover how Certara’s dedicated project management and pharmacometric support helped an emerging biotech company fast-track…
CertaraJuly 2, 2025
The Medicine Maker: The Biosimulation Generation
The article, The Biosimulation Generation, explores the transformative potential of biosimulation in pharmaceutical R&D as…
Danielle PillsburyJuly 1, 2025
5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address
June 30, 2025 Drug development is increasingly defined by its complexity. Teams must navigate rising…
CertaraJune 30, 2025
